Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-180: Pembrolizumab in advanced esophageal cancer
NCT02559687Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in esophageal carcinoma, esophagogastric junction carcinoma, sponsored by Merck & Co.. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
esophageal carcinomaesophagogastric junction carcinoma
Beyond the preview
Go deeper on NCT02559687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559687.